Bladder Cancer Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014


#219147

N/A

DelveInsight

$ 2000

In Stock

 

The Report will be Dispatched in 3 Working days. 

 

DelveInsights, Bladder Cancer- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014, report provides comprehensive insights about phase III pipeline drugs and marketed drugs across the indication. A key objective of the report is to establish the understanding for API Manufacturers for marketed and Phase III pipeline drugs across the different countries and regions. While the leading brands, companies and chemicals are considered thoroughly, the report also provides details on the drug master filings across the US, Europe and Asia specifically China and India. The research, analysis also presents the global sales forecasts data till 2015. The report is also giving insight about the patent and exclusivity details of all the drugs across the indication. 

 

Data Sources

 

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by DelveInsight team of industry experts.

 

Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.

 

Scope 

 

  • A snapshot of the global Market therapeutics scenario for  Bladder Cancer.
  • A review of the marketed products under prescription for  Bladder Cancer, regulatory information and marketing status.
  • Coverage of global patent coverage and detailed commentaries on the US patent challenges. 
  • Graphical representation of investigational products for patent expiry and market exclusivities across the globe.
  • Product profiles for marketed products for  Bladder Cancer with complete description of mechanism of action, therapeutic class, target, route(s) of administration and chemical details.
  • Coverage of API Manufacturers for  Bladder Cancer drugs in the United States, Europe and Asian Regions with location details.
  • Coverage of Regulatory filings in the US, Europe, and Asia specifically India and China for  Bladder Cancer drugs.
  • Coverage of Route of Synthesis of Active Pharmaceutical Ingredient associated with  Bladder Cancer drugs.
  • Coverage of  Bladder Cancer Phase III pipeline products featuring sections on product description, mechanism of action, Chemical details and research & development progress.
  • Coverage of the United States Drug Master File (US DMF) available for Phase III Pipeline Drugs.
  • Key discontinued Marketed products.
  • Global Sales Figure from 2011-2015.

 

Reasons to buy 

 

  • Evaluate the marketing status and exclusivity details of  Bladder Cancer key products to exploit opportunities for generic drug development opportunities.
  • Identify and understand important and diverse types of therapeutics under Phase III development for  Bladder Cancer.
  • Design effective counter-strategies to gain competitive advantage by identifying the key patent expiry details and exclusivity with respect to  Bladder Cancer.
  • API intelligence over marketed drugs for  Bladder Cancer and gaining primary intelligence over active ingredients manufacturers across the globe.
  • API intelligence over leading Phase III pipeline drugs.
  • Develop and designstrategies by identifying the API manufacturers for Phase III pipeline products to enhance and expand business potential and scope.
  • Understanding the scope of the Phase III Drugs with nil regulatory filings.
  • Understanding the chemical route of synthesis of approved drugs for  Bladder Cancer.
  • Uncovering opportunities in the rapidly growing the US markets.

Table of Content

 

Indication Overview 

Marketed Drugs Assessment 

Marketed Details of Drugs by Application Type

Marketed Details of Drugs (NDA) by Marketing Status

Marketed Details of Drugs by Patent Expiration Timeline

The Active Pharmaceutical Ingredient (API) Manufacturers Assessment 

The API Manufacturers by the United States Drug Master File (US DMF) Status

The API Manufacturers by the US DMF Status (Drug Specific)

The Active Pharmaceutical Ingredient (API) Manufacturers Assessment for Phase III Pipeline Drugs

The API Manufacturers by the US DMF Status (Drug Specific) 

Drugs Market Data and Forecasted Sales Figures (2011-2015)

Marketed Drugs Information

Drugs Description

Route of Synthesis 

Global Active Pharmaceutical Manufacturers

Approval Status

Patent and Exclusivity Details

Company Overview

Phase III Drugs Information

Phase III Drugs Description

The United States Drug Master Filings (US DMF)

Discontinued Drugs Information

 

Bladder Cancer Therapeutic Market, US, Marketed Drugs by Application Type, 2014

Bladder Cancer Therapeutic Market, US, Marketed Drugs by Marketing Status, 2014

Bladder Cancer Therapeutic Market, US, (Year), 2014

Bladder Cancer Marketed Drugs, API Manufacturers by US DMF Status, 2014

Bladder Cancer Marketed Drugs, US DMF Status Drug Specific (Number), 2014

Bladder Cancer Phase III Pipeline Drugs, US DMF Status Drug Specific (Number), 2014

Bladder Cancer Therapeutic Market, Global Sales (in million USD), 2014

Bladder Cancer Marketed Drugs, API Manufacturers, Global, 2014

Bladder Cancer Phase III Pipeline Drugs, United States Drug Master File (DMF), 2014

Discontinued Drugs for Bladder Cancer, 2014

 

Bladder Cancer Therapeutic Market, US, Marketed Drugs by Application Type (%), 2014

Bladder Cancer Therapeutic Market, US, Marketed Drugs by Marketing Status (%), 2014

Bladder Cancer Therapeutic Market, US, (Year), 2014

Bladder Cancer Marketed Drugs, API Manufacturers by US DMF Status (%), 2014

Bladder Cancer Marketed Drugs, US DMF Status Drug Specific (Number), 2014

Bladder Cancer Phase III Pipeline Drugs, US DMF Status Drug Specific (Number), 2014 

Bladder Cancer Therapeutic Market, Global Sales (in million USD), 2014

Bladder Cancer Marketed Drugs, Patent/Exclusivity Expiry (Year), 2014